PT-141, also known as bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It acts on melanocortin receptors (primarily MC3R and MC4R) in the central nervous system to enhance sexual desire and arousal.
Unlike PDE5 inhibitors (Viagra, Cialis) which work on blood flow, PT-141 works through the brain's arousal pathways, making it effective for both desire and arousal components of sexual function.
An FDA-approved version of bremelanotide (Vyleesi®) is available for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 is used off-label for both men and women.
FDA-approved for HSDD in premenopausal women; off-label use in men and other populations.
PT-141 works through the brain's melanocortin system:
Because it works centrally rather than peripherally, PT-141 addresses desire and arousal rather than just erectile mechanics.
Phase 3 clinical trials (RECONNECT) demonstrating bremelanotide's efficacy in treating hypoactive sexual desire disorder in premenopausal women.
Study showing PT-141 induced erections in men with erectile dysfunction through central melanocortin receptor activation.
Review of melanocortin receptor signaling and its role in regulating sexual behavior and arousal.
If you're using a browser with advanced ad blocking security measures, the above study links may not work. You can copy the link and paste it into a new window.
Disclaimer: The information on this page was generated with the assistance of artificial intelligence and compiled from publicly available sources. While efforts are made to ensure accuracy, information may be incomplete, outdated, or incorrect and should not be relied upon as medical advice.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded drugs have not been approved by the FDA; have not been reviewed by the FDA for safety, efficacy, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use. The processes by which the compounded drugs are manufactured have not been reviewed by the FDA. FDA approved products containing semaglutide and tirzepatide are available.